Workshop 5: Combined Exposures & Synergistic Effects



Chair: A. Kortenkamp

Rapporteur: B. Meek

Université d'Ottawa | University of Ottawa




L'Université canadienne Canada's university



Outline

- State of the Art Assessment of Mixtures (aka "Combined Exposures to Multiple Chemicals")
- Recent International Developments
 - WHO IPCS Framework/Case Studies
- Needs/Issues
- Path Forward

Assessment for Combined Exposures State of the Art



Questions for Consideration

- Need for assessments of combined exposures
- Barriers/challenges to assessments of combined exposures?
- Appropriate criteria for consideration of combined exposures? (toxicological similarity)
- Suggestions for further elaboration of approaches for combined exposures assessment?

Need for Combined Exposures Assessments

- Increasing legal imperative
 - Addressed informally to some degree in other programs
- Increasingly exposed to combinations
- Public demand/expectation
- Protection of public health

But:

- Extent of risk is currently unknown/needs addressing
 - Synergy rare
- Need for careful and effective communication moving forward

Some Barriers

- Lack of legal mandate
- Diverging views on grouping criteria
- Limitations of available approaches/tools/data
 - Chemical specific vs. disease outcomes
 - Potential contribution of epidemiology
 - Better integration of toxicological/epidemiological approaches
 - Exposure assessment
 - Dichotomous approach to cancer/non-cancer effects

Grouping Criteria

- Context dependent
- Co-exposure a prerequisite Increasing need to consider:
- Common effect/endpoint/disease
- Common early key events/pathways
- Common metabolite,

Rather than (e.g.) chemical similarity

Path Forward


- Move forward collectively, considering case studies within a common framework
- Identifying the most common/relevant scenarios, mixtures of concern
 - Expanding to include non chemical stressor
 - Pharmaceuticals
 - Indoor air
- Evolving approaches
 - Common early key events/pathways
 - Common effect/endpoint/disease
 - Common metabolite
 - Potential to identify critical "drivers"?

Contents of the WHO/IPCS Framework

- Provides overview harmonizing construct
 - Builds upon other related initiatives and methodologies
- When to conduct a combined assessment
- Generic description of the framework approach
 - Hierarchical structure with iterative consideration of exposure and hazard
- Three case studies (examples, only)
 - Priority setting for drinking water contaminants
 - Screening assessment on PBDEs
 - Full assessment on conazoles

Problem Formulation

Nature of exposure? Is exposure likely? Co-exposure within a relevant timeframe? Rationale for considering compounds in an assessment group?



Development – WHO IPCS Combined Exposures

- Overview workshop to review terminology & methodology in March/o7
 - 27 invited senior experts from relevant agencies worldwide; 5 reps from partnering organizations
 - Recommendations to harmonize terminology
- Post workshop development of framework/case studies
 - WHO IPCS
 - International Life Sciences Institute (ILSI)
 - European Centre for Ecotoxicology & Toxicology of Chemicals (ECETOC)
- Framework & case studies posted for public comment
 - Comment period closed October 31/09
- Framework revised based on public comment
 - Feb/2010 meeting London
- In publication
- Joint OECD/WHO/ILSI workshop
 - February/11

This paper was produced for a meeting organized by Health & Consumers DG and represents the views of its author on the subject. These views have not been adopted or in any way approved by the Commission and should not be relied upon as a statement of the Commission's or Health & Consumers DG's views. The European Commission does not guarantee the accuracy of the data included in this paper, nor does it accept responsibility for any use made thereof.